GlassScriptPhysician profile
Nora Agajelu
NPI 1053589028
$2,894.72
in general payments reported to CMS, 2019-2025
36 companies · $590 in 2025
The $590 reported for 2025 was more than what 75% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $715 · 2022: $656 · 2023: $503 · 2024: $430 · 2025: $590.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,524.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,524.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $371.73 | 2021-2025 | Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $305.26 | 2021-2025 | |
| Abbvie INC. | $289.01 | 2021-2024 | Ubrelvy, Vraylar |
| Dexcom, INC. | $266.95 | 2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $209.88 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $203.84 | 2021-2025 | Trelegy Ellipta |
| Abbott Laboratories | $191.24 | 2021-2023 | Freestyle Libre 3 |
| Lilly USA, LLC | $147.70 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $135.39 | 2022-2023 | Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $70.19 | 2021-2022 | |
| Astellas Pharma US INC | $68.47 | 2022-2024 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $64.98 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.50 | 2021-2023 | Jardiance |
| Biohaven Pharmaceuticals, INC. | $54.90 | 2021 | |
| Gilead Sciences, INC. | $51.97 | 2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $25.28 | 2022 | |
| Inspire Medical Systems, INC. | $24.97 | 2025 | Inspire |
| Globus Medical, INC. | $24.10 | 2025 | Senza |
| Amarin Pharma, INC. | $23.30 | 2021 | |
| Horizon Therapeutics Plc | $22.18 | 2023 | Krystexxa |
| Jazz Pharmaceuticals INC. | $22.18 | 2021 | |
| Global Blood Therapeutics, INC. | $21.73 | 2022 | |
| Vanda Pharmaceuticals INC. | $21.54 | 2022 | |
| Eisai INC. | $21.15 | 2021 | |
| Boston Scientific Corporation | $20.89 | 2024 | Bodyguardian |
| Takeda Pharmaceuticals U.S.A., INC. | $19.86 | 2021 | |
| Corcept Therapeutics | $19.84 | 2024 | Korlym |
| Arbor Pharmaceuticals, INC. | $17.64 | 2021 | |
| Sumitomo Pharma America, INC. | $17.59 | 2023 | Gemtesa |
| Nevro Corp. | $15.98 | 2023 | Senza |
| Merck Sharp & Dohme LLC | $15.13 | 2021 | |
| Pfizer INC. | $14.81 | 2023 | |
| Lundbeck LLC | $14.31 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.42 | 2024 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $12.59 | 2021 | |
| Medtronic, INC. | $12.22 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nora Agajelu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.